Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review by unknown
O’Kane et al. Clin Sarcoma Res  (2015) 5:17 
DOI 10.1186/s13569-015-0032-0
RESEARCH
Perioperative chemotherapy in the 
treatment of osteosarcoma: a 26-year  
single institution review
G M O’Kane1*, K A Cadoo2, E M Walsh1, R Emerson1, P Dervan3, C O’Keane3, B Hurson4, G O’Toole4, S Dudeney4, 
E Kavanagh5, S Eustace5 and D N Carney1
Abstract 
Background: Chemotherapy in the multimodality treatment of osteosarcoma has improved survival. Reported 
outcomes on adult patients are limited. Poor necrosis rates post neoadjuvant chemotherapy (NAC) is considered an 
adverse prognostic factor and attempts have been made to improve survival in this group.
Patients and methods: Adult and young adult patients diagnosed with osteosarcoma between January 1986 and 
August 2012 were retrospectively reviewed. Patients identified were stratified according to stage (localised or meta-
static) and age (≤40 and >40 years). Event free survival (EFS) and overall survival (OS) outcomes were determined. In 
patients with localised disease ≤40 years, survival was assessed according to necrosis rates post NAC (<90 and ≥90%). 
NAC consisted of two cycles of methotrexate alternating with doxorubicin/cisplatin (MAP) followed by definitive 
surgery. Those with ≥90% tumour necrosis continued on MAP. Patients with <90% necrosis received ifosfamide and 
etoposide (IE) post operatively.
Results: A total of 108 patients were reviewed and 97 were included. Median age was 23 years (range 16–75) and 
70% of patients were male. Five year EFS and OS across all groups was 57% and 63% respectively. Of the patients with 
localised disease (N = 81), 5-year overall survival (OS), with a median follow up of 7 years (2–26) was 70% (p < 0.0001). 
Patients aged 16–40 (N = 68) with localised osteosarcoma had a significantly improved 5-year OS (74%) compared to 
those >40 years (N = 13) (42%) (p = 0.004). Of the 68 patients with localised osteosarcoma ≤40 years, 62 were evalu-
ated according to necrosis rates post MAP. In 33 patients who achieved ≥90% necrosis and continued MAP, 5-year OS 
was 82%. In 29 patients who had <90% tumour necrosis and received adjuvant IE, 5-year OS was 68% (p = 0.15). Mul-
tivariate analysis confirmed age and stage as prognostic factors but not poor necrosis rates in our treated population.
Conclusions: Long-term survival outcomes in a predominantly adult Irish population are similar to large reported 
trials. Age and stage at diagnosis are prognostic. Postoperative ifosfamide/etoposide alone in patients with poor 
necrosis rates is a feasible regimen, but its role in the adjuvant setting remains uncertain.
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Background
Osteosarcoma is a rare tumour type occurring with 
an incidence of 0.2–3/1,00,000 per year in Europe [1]. 
Despite this, it is the most common primary tumour of 
bone (excluding multiple myeloma), which occurs with 
a bimodal age distribution. The first peak, in adolescents 
and young adults, possibly coincides with the pubertal 
growth spurt. The second peak in patients over 65 years 
may result from the development of osteosarcoma as 
a secondary malignancy [2, 3]. The metaphyses of long 
bones are the most commonly affected site [3] with more 
than 50% of occurrences adjacent to the knee joint [4].
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Prior to the 1970s surgery alone cured <20% of 
patients; the majority of deaths resulted from the rapid 
development of lung metastases [5]. Since the incorpo-
ration of chemotherapy, multimodality treatment has 
improved survival to approximately 70% at 5 years with 
little improvement in the last two decades [4, 6, 7]. Tri-
als demonstrating this survival have largely included pae-
diatric patients and outcomes in adult patients alone are 
limited.
Where feasible, the standard of care for patients with 
localised extremity osteosarcoma involves NAC followed 
by definitive surgical resection and adjuvant chemother-
apy [8]. Although NAC versus immediate surgery and 
adjuvant chemotherapy has not been shown to improve 
OS [6], it does allow for optimal surgical planning [9] and 
avoids the need for amputation in most patients. Chemo-
therapy protocols have generally incorporated four active 
agents: Methotrexate with leucovorin rescue, doxoru-
bicin, cisplatin and ifosfamide [10]. The most appropri-
ate combination of these drugs however, continues to be 
debated [8].
NAC also provides prognostic information on tumour 
necrosis rates, which has been used to tailor postop-
erative treatment. Based on the Huvos grading sys-
tem, patients with ≥90% necrosis are considered good 
responders and those with <90% necrosis as poor 
responders [11]. Large trials have demonstrated inferior 
5-year survival rates in patients with a poor response ver-
sus those with a good response (45–56% versus 71–80% 
respectively) [4, 12–14]. Attempts in the past have failed 
to improve survival by modifying adjuvant treatment in 
poor responders and a recent meta-analysis found no 
benefit in switching or intensifying drugs [7, 15, 16]. Ifos-
famide/etoposide (IE) has been shown to have efficacy in 
the metastatic setting [17] and is considered safe when 
added to MAP [18]. MAPIE formed the adjuvant arm 
of poor responders in the EURAMOS-1 trial and pro-
visional results reveal no improvement in survival [19]. 
At our institution patients with poor necrosis rates have 
been receiving postoperative IE alone since 1986.
In this article we review the outcomes of a predomi-
nantly adult population over a 26-year period and assess 
the impact of switching chemotherapy to IE in patients 
with <90% necrosis rates post neoadjuvant MAP.
Patients and methods
Patient population
A retrospective review was undertaken of patients with a 
diagnosis of osteosarcoma seen by the oncology depart-
ment at the Mater Misericordiae University Hospital 
from January 1986 to August 2012. This hospital has 
been a tertiary referral centre for the systemic treat-
ment of adult osteosarcoma, collaborating with Cappagh 
Hospital, the national orthopaedic hospital, where the 
majority of bone tumour surgeries are performed. All 
pathology was reviewed at our institution. During the 
period analysed, three orthopaedic surgeons performed 
98% of the surgeries and the same oncologist delivered 
systemic treatment in all patients.
Patient details were obtained from the pathology 
department database and corroborated with the hospi-
tal information system search for patients with a diag-
nosis of osteosarcoma. Medical records of the patients 
collected were then appraised. Data was obtained on 
all patients with a histological diagnosis of high-grade 
osteosarcoma. We included patients with extremity or 
truncal high-grade osteosarcoma who received systemic 
treatment. Patients with craniofacial osteosarcoma, 
which is considered less aggressive, and those who did 
not receive chemotherapy were excluded. Patients were 
stratified according to stage: localised and metastatic dis-
ease at presentation and then further classified by age: 
≤40 and >40  years. Those patients with localised dis-
ease ≤40  years, who received NAC were subsequently 
assessed according to necrosis rates based on the Huvos 
grading system [11]: poor responders(<90% necrosis, 
grade I–II) and good responders (≥90% necrosis, grade 
III–IV).
Staging and treatment details
Staging was performed using a plain film, radionuclide 
bone scan and/or magnetic resonance imaging (MRI) of 
the affected limb. Computed tomography (CT) thorax, 
abdomen and pelvis (TAP) and Chest X-Ray (CXR) com-
pleted radiological staging. More recently FDG PET/CT 
has been incorporated into routine work up. Full blood 
count and biochemical analyses were also measured 
at diagnosis and throughout treatment. The intended 
operating surgeon performed diagnostic biopsies where 
possible. All patients were discussed at our institutional 
multidisciplinary team meeting (MDT) at diagnosis, post 
NAC and post resection.
The systemic treatment of resectable osteosarcoma at 
our institution consists of two cycles of high dose meth-
otrexate 8  g/m2 alternating with doxorubicin 25  mg/m2 
days 1–3 and cisplatin 100 mg/m2 on day 1 (MAP), fol-
lowed by definitive surgery and adjuvant chemotherapy 
(Additional file 1: Table S1). Patients with tumours which 
upon histological review demonstrate ≥90% necrosis 
continue MAP for a further two alternating cycles while 
those who have <90% necrosis rates switch to ifosfamide 
1,800  mg/m2 with mesna 1,800  mg/m2 days 1–5 and 
etoposide 100 mg/m2 days 1–5 for a total of four cycles 
(Additional file  1: Table  S1). Dosing and scheduling of 
chemotherapy administered was confirmed with the 
pharmacy department.
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Patients with metastases at diagnosis who were consid-
ered resectable were treated with the same protocol and 
at surgery had resection of the primary lesion and metas-
tases where applicable.
Close surveillance was initiated upon completion of 
adjuvant treatment. Patients were seen 3  monthly for 
the first 2 years with a CXR; a CT Thorax was performed 
every 6  months. Thereafter patients were reviewed 
4–6  monthly with a CXR until year 5 at which point 
annual follow-up was commenced.
Data collection
Demographic and clinical details were extracted from 
the patient’s medical records. Information on histology 
was obtained from the laboratory report system. Data 
collected included age, sex, stage at diagnosis, tumour 
site, type of operation, percentage necrosis, chemother-
apy regimen used and number of cycles administered. 
Relapse date and site, together with survival and follow 
up information was also recorded.
Statistical analysis
Demographic details and treatment variables are 
reported by descriptive statistics. EFS and OS were com-
puted from time of tissue biopsy until first recurrence or 
death respectively. Time of cut off for analyses was July 
31st 2014. The Kaplan–Meier survival analysis method 
and the log rank test were used to estimate survival prob-
ability and compare survival within stratified groups. The 
Cox Regression model was used to assess the prognostic 
impact of age, stage and necrosis rates on survival. Analy-
ses were conducted using SPSS 20.0
Results
Patient characteristics
Between January 1st 1986 and July 31st 2012 108 adult 
patients with a diagnosis of osteosarcoma were reviewed 
by medical oncology. Eight patients who did not receive 
chemotherapy due to poor performance status (median 
age 73 years, range 46–81) and three patients with crani-
ofacial disease were excluded. A total of 97 patients were 
included. Detailed baseline patient demographics and 
tumour characteristics are available in Additional file  2: 
Table S2. Specific high-grade subtypes were incompletely 
reported during the time period and not available for 
analysis. Five patients were under 18 years (16–17 years) 
with the majority (95%) ≥18  years. Median age over-
all was 23  years (16–73). Seventy percent of patients 
were male. The most common site of tumour was the 
femur (54%) followed by the tibia (20%). Of the total 
patients included (N = 97) 81 (84%) had localised disease 
and 16 (16%) had metastatic osteosarcoma at diagno-
sis. In patients with localised disease, 68/81 (84%) were 
≤40 years (16–40) and in patients with metastatic disease 
at diagnosis, 11/16 (68%) were ≤40  years (17–40). Fol-
low-up for all patients ranged from 2 to 28.6 years with a 
median of 7 years.
Surgical treatment
Limb-salvage surgery was performed in 70% of patients 
with disease of the extremities (N  =  90). Of these 90 
patients 77 had localised disease and 13 metastatic dis-
ease. Limb-salvage was possible in 77% of patients with 
localised disease and was performed in only 31% of 
patients with metastatic disease (4/13) (Additional file 2: 
Table S2). Notably the period of this review from 1986 to 
2012 has seen changes in approaches to the surgical man-
agement of extremity osteosarcoma with the increasing 
use of limb-salvage techniques in recent years [20, 21].
Chemotherapy
In patients with localised disease (N  =  81), 618 of 
planned 648 chemotherapy cycles were completed (95%). 
Eight patients (10%) did not complete the intended cycles 
of treatment. Four patients ≥40 years with localised dis-
ease, developed grade 3–4 toxicities, as did three patients 
≤40  years. One further patient ≤40  years refused two 
final cycles of adjuvant treatment. Of the 16 patients with 
metastatic disease 11 (70%) completed intended first line 
treatment.
Survival outcomes
The 5-year EFS and OS across all groups was 57 and 
63% respectively. Stage at diagnosis was prognostic. 
Patients with localised disease (N  =  81) had a signifi-
cantly improved 5-year OS compared to those with 
metastatic disease at diagnosis (N =  16), 70 versus 25% 
p < 0.0001 (all age groups) (Figure 1a). EFS was 65 versus 
13% p < 0.0001 (Figure 1b). Despite unbalanced numbers 
in each group age was also prognostic. EFS in localised 
disease ≤40  years (N =  68) was 70% compared to 30% 
in those >40 years (N = 13) (p = 0.009). Corresponding 
5-year OS was 74% compared to 42%. (p =  0.004) (Fig-
ure 2a, b). Seven of the 13 patients >40 years (median age 
54 years, range 44–74) with localised disease have died. 
Of these four were unable to complete chemotherapy due 
to toxicity. Multivariate analysis using the Cox Regres-
sion model confirmed the prognostic impact of age and 
stage for EFS (p = 0.001 and p = 0.001 respectively) and 
for OS (p = 0.002 and p = 0.001 respectively). 
Relapsed disease in patients with localised osteosarcoma 
at diagnosis
Of the 81 patients with localised disease, 32 (40%) 
experienced recurrences. This included seven patients 
>40 years (54% of all patients >40 years). The lung was site 
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of first recurrence in 22/32 (69%) patients, with locally 
recurrent disease in nine patients. Three of these nine 
patients developed lung metastases within 1  year and 
one patient developed lung metastases 4 years later. One 
patient developed brain metastases as first documented 
recurrence but was also found to have lung metastases 
post complete imaging. Of the 32 patients who recurred, 
11 patients (9 ≤ 40 years and 2 > 40 years) are alive and 
disease free with a median follow-up of 10.3 years (range 
4.8–27.1). Four of these 11 patients developed local 
recurrences and were treated with surgery including one 
amputation; the remaining seven patients had thoracoto-
mies for lung metastases (median number of thoracoto-
mies 1; range 1–3).
Impact of switching chemotherapy in patients with poor 
necrosis (localised ≤40 years)
Of the 68 patients with localised disease ≤40  years, 62 
were eligible for assessment of survival according to 
Figure 1 a Overall survival in patients with localised disease versus 
metastatic disease. b Event free survival in patients with localised 
disease versus metastatic disease.
Figure 2 a EFS and b OS in localised disease according to age.
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necrosis rates. The remaining six patients had upfront 
surgery without NAC and were thus excluded. Five of 
these six patients were initially thought to have parosteal 
osteosarcoma and one patient a chondrosarcoma. Path-
ological review of tumour specimens post resection 
revealed high-grade osteosarcoma. These six patients all 
received eight cycles of chemotherapy in the adjuvant 
setting and five are still alive with a median follow up of 
3.8 years (2.2–14.4).
The 62 patients included all had initial biopsies and 
post NAC histology reviewed at our institution. Median 
follow-up time in this group was 9.4 years (range 2–28.6). 
33 patients demonstrated ≥90% necrosis post MAP and 
29 patients <90% necrosis. There was no significant dif-
ference in 5  year-EFS in good responders (81%) and in 
poor responders (64%) (p =  0.18) (Figure  3a). Five year 
OS was 82% in those with ≥90% necrosis versus 68% in 
those with <90% necrosis; this result was again not sta-
tistically significant p = 0.15 (Figure 3b). When included 
in multivariate analysis, necrosis rates post NAC was 
not prognostic for EFS (p = 0.9) or OS (p = 0.62) in our 
cohort (Additional file 3: Table S3).
Outcomes in patients with metastatic disease at diagnosis
Sixteen patients (16%) had evidence of metastases at 
diagnosis and 5-year OS was 25%. Lung metastases were 
present in 13 patients and 3 patients had multifocal dis-
ease. Of the 13 patients with lung metastases 7 had thora-
cotomies, 2 at primary resection and 5 at recurrence. The 
median number of thoracotomies was 1 (range 1–4). Two 
patients with metastases at presentation, 1 with multifo-
cal disease and 1 with lung metastases are still alive 8.3 
and 15.4 years later.
Discussion
This is a retrospective study of predominantly adult 
osteosarcoma patients treated systemically at a single 
institution over 26  years. We have established that long 
term overall survival outcomes in this Irish population 
are comparable to previously reported large clinical tri-
als. This study has also demonstrated the feasibility of IE 
postoperatively in patients with a poor response to neo-
adjuvant MAP.
Adult patients are generally underrepresented in osteo-
sarcoma trials despite approximately half of patient diag-
noses occurring in those over 20 years. [22] The median 
age in our study was 23  years with 95% of patients 
≥18 years and 70% of patients included were male. The 
male preponderance in osteosarcoma is well docu-
mented and although the proportion is slightly higher 
than reported ratios [3, 23] this may be explained by the 
older age of the patients included, as peak incidence in 
the female population occurs earlier [23].
Inferior outcomes have been reported in patients 
over 40 [24, 25] and over 65 years [26]. A meta-analysis 
reported by Harting et  al. investigating age as a prog-
nostic factor in osteosarcoma, revealed that patients 
aged 21–40 (N = 110) had the same outcomes as that of 
the paediatric population with inferior survival in those 
>40 years (N =  56) [27]. This study acknowledges how-
ever that age alone is unlikely to contribute to inferior 
outcomes, but rather site, size and tumour necrosis rates 
in this group. In our study 5-year OS for all 97 patients 
included was 64%, improving to 74% when selecting 
Figure 3 a EFS and b OS in patients with localised disease <40 years 
according to necrosis rates.
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patients aged 16–40 years with localised disease (N = 68). 
A small number of patients (N =  18) were >40 years at 
diagnosis. Of these, patients with localised disease at 
presentation (N = 13) had a significantly inferior survival 
at 5 years (45%) compared to patients ≤40 years. Seven 
of thirteen patients died and in four of these less than 
50% of chemotherapy cycles were completed as a result 
of toxicity. The remaining three patients all had tumours 
>8  cm, one of whom had positive surgical margins; all 
three demonstrated poor necrosis rates post NAC. These 
factors are likely to have impacted on survival, however 
numbers are too small to make further conclusions. One 
of the largest studies in patients over 40 years reported by 
Grimer et al. [25] describes 238 patients with non meta-
static osteosarcoma and reports a 5-year survival of 46%. 
Other studies report superior survival rates of 55–62% at 
5 years [4, 28]. It is therefore likely that other patient and 
tumour characteristics contribute to outcomes.
Less than 20% of patients with osteosarcoma will pre-
sent with de novo metastatic disease [29]. In our cohort 
16/97 (16%) patients had metastatic disease at diagnosis. 
The 5-year OS of 25% in this group is consistent with pre-
vious studies, which highlight number and resectability 
of metastases as prognostic in those with de novo meta-
static disease [29, 30]. Of patients with localised disease 
at diagnosis who recurred in our study, 11/32 (34%) were 
salvaged with surgery. Seven of these patients were ren-
dered disease free post thoracotomies. The aggressive 
surgical management of recurrent osteosarcoma with 
complete clearance is necessary for long-term survival 
and is well described [31–33]. Duration of relapse free 
interval and number of lesions are considered prognostic 
factors [31].
When evaluating the impact of poor necrosis rates on 
survival we were able to include 62 patients with localised 
disease ≤40 years who received NAC. Responsiveness to 
NAC has been established as a predictor of survival [4, 
12–14, 34].
The COSS, EOI and IOR groups have reported 5-year 
survival rates of 55.5, 45 and 56% respectively for poor 
responders with localised osteosarcoma [4, 12, 35]. Mul-
tiple studies have attempted to improve outcomes in 
this poor prognostic group by switching drugs or inten-
sifying treatment, however a meta-analysis published by 
Anninga et al. [16] showed no benefit to either method.
MAP as a neoadjuvant regimen has been used since the 
1980s and is considered standard of care in the United 
States [36]. This combination formed the backbone of 
the international multi-group EURAMOS-1 trial [37], 
the largest trial conducted in osteosarcoma. Survival out-
comes in osteosarcoma have plateaued in recent decades 
and this group attempted to improve outcomes in both 
good and poor responders. The addition of IFN alpha-2b 
to MAP in good responders has recently been reported 
and failed to enhance survival [38]. Patients with poor 
necrosis rates were randomized to remain on MAP post-
operatively or switch to MAP and IE.
The role of ifosfamide in osteosarcoma has been contro-
versial. It has been shown to be active in the metastatic set-
ting [17, 39] and has shown improvements in recurrence 
free survival and overall survival in patients at first recur-
rence [32]. The use of ifosfamide as a fourth drug in the 
neoadjuvant setting however does not improve histologic 
response and increases hematological toxicity [40]. When 
IE is added to MAP in poor responders post operatively 
results have differed. The IOR group have found favorable 
outcomes with use of ifosfamide [41] however the Scan-
dinavian Sarcoma Group (SSG) failed to show a benefit 
of the addition of IE to MAP adjuvantly in poor respond-
ers [42]. Early results from EURAMOS-1 have also failed 
to show a benefit of additional IE to MAP in poor necro-
sis patients. It should be noted that fewer patients in this 
group received the intended doses and more toxicities 
were experienced [19]. In our patients survival at 5 years 
was 82% in good responders versus 68% in those treated 
with IE alone postoperatively. This difference was not sta-
tistically significant but suggests that IE is an acceptable 
adjuvant regimen in patients with poor necrosis rates.
Conclusions
Adult and young adult osteosarcoma patients under 
40  years with localised osteosarcoma treated at our insti-
tution have equivalent outcomes compared to paediatric 
patients. Patients over 40  years are more challenging and 
are more likely to experience toxicity. Switching chemo-
therapy to ifosfamide/etoposide alone in patients with poor 
necrosis rates post neoadjuvant methotrexate, doxorubicin, 
cisplatin is a feasible regimen, but where these drugs fit in 
the treatment paradigm remains to be established.
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